For example, immune microenvironment modulation, such as the inhibition of CCR5 + T cell accumulation in the tumor microenvironment, can improve the efficacy of anti-TGF-β/PD-L1 bispecific antibody therapy. This evidence concerns the gene TGFB1 and neoplasm.